Hypericin-mediated photodynamic therapy induces apoptosis of myoloma SP2/0 cells depended on caspase activity in vitro

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Zhang, Junping ^a   Shao, Linxiang ^b   Wu, Chunlin ^c   Lu, Hongfei ^b   Xu, Ruian ^a  

^a HUAQIAO UNIVERSITY   (China)

^b ZHEJIANG NORMAL UNIVERSITY   (China)

^c FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Caspase; Hypericin mediated photodynamic therapy; Multiple myeloma; SP2 0 cells

Indexed keywords

CASPASE 3; DNA FRAGMENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVITY; FLUORESCENCE MICROSCOPY; HYPERICIN MEDIATED PHOTODYNAMIC THERAPY; IN VITRO STUDY; INCUBATION TIME; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MTT ASSAY; MULTIPLE MYELOMA CELL LINE; NONHUMAN; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RADIATION DOSE; SP2 0 CELL LINE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

EID: 84961664577     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-014-0136-2     Document Type: Article

References (48)

1. BladÉ J, Samson D, Reece D, Apperley J, BJÖrkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998, 102 (5): 1115-1123.
2. Greene FL: AJCC Cancer Staging Manual, Volume 1. 2002, Springer, New York
3. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC: Multiple myeloma. Lancet. 2009, 374 (9686): 324-339.
4. Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma. Arch Intern Med. 1990, 150 (8): 1693-1695.
5. Twomey JJ: Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med. 1973, 132 (4): 562-565.
6. Dispenzieri A, Kyle RA: Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol. 2005, 18 (4): 673-688.
7. Takiar R, Nadayil D, Nandakumar A: Projections of number of cancer cases in India (2010-2020) by cancer groups. Asian Pac J Cancer Prev. 2010, 11 (4): 1045-1049.
8. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA: International staging system for multiple myeloma. J Clin Oncol. 2005, 23 (15): 3412-3420.
9. Oleinick NL, Morris RL, Belichenko I: The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci. 2002, 1 (1): 1-21.
10. Sieber F: Phototherapy, photochemotherapy, and bone marrow transplantation. J Hematother. 1993, 2 (1): 43-62.
11. Brasseur N, Menard I, Forget A, Jastimi R, Hamel R, Molfino N, Lier J: Eradication of Multiple Myeloma and Breast Cancer Cells by TH9402mediated Photodynamic Therapy: Implication for Clinical Ex Vivo Purging of Autologous Stem Cell Transplants. Photochem Photobiol. 2000, 72 (6): 780-787.
12. Huang H, Chen Y, Chen W, Wu Y: Purging efficacy of ZnPcH(1)-based photodynamic therapy on chronic myeloid leukemia bone marrow. Int J Lab Hematol. 2011, 33 (5): 477-482.
13. Barth BMI, Altinoğlu E, Shanmugavelandy SS, Kaiser JM, Crespo-Gonzalez D, DiVittore NA, McGovern C, Goff TM, Keasey NR, Adair JH: Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano. 2011, 5 (7): 5325-5337.
14. Shahzidi S, Čunderlíková B, Wiȩdłocha A, Zhen Y, Vasovič V, Nesland JM, Peng Q: Simultaneously targeting mitochondria and endoplasmic reticulum by photodynamic therapy induces apoptosis in human lymphoma cells. Photochem Photobiol Sci. 2011, 10 (11): 1773-1782.
15. Agostinis P, Vantieghem A, Merlevede W, de Witte PA: Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol. 2002, 34 (3): 221-241.
16. Lavie G, Mazur Y, Lavie D, Meruelo D: The chemical and biological properties of hypericin-a compound with a broad spectrum of biological activities. Med Res Rev. 1995, 15 (2): 111-119.
17. Cole CD, Liu JK, Sheng X, Chin SS, Schmidt MH, Weiss MH, Couldwell WT: Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in a GH4C1 rat tumor model. J Neurooncol. 2008, 87 (3): 255-261.
18. Zupko I, Kamuhabwa AR, D'Hallewin MA, Baert L, De Witte PA: In vivo photodynamic activity of hypericin in transitional cell carcinoma bladder tumors. Int J Oncol. 2001, 18 (5): 1099-1105.
19. Liu CD, Kwan D, Saxton RE, McFadden DW: Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo. J Surg Res. 2000, 93 (1): 137-143.
20. Vantieghem A, Assefa Z, Vandenabeele P, Declercq W, Courtois S, Vandenheede JR, Merlevede W, de Witte P, Agostinis P: Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis. Involvement of cytochrome c and procaspase-3 activation in the mechanism of apoptosis. FEBS Lett. 1998, 440 (1-2): 19-24.
21. Berlanda J, Kiesslich T, Oberdanner CB, Obermair FJ, Krammer B, Plaetzer K: Characterization of apoptosis induced by photodynamic treatment with hypericin in A431 human epidermoid carcinoma cells. J Environ Pathol Toxicol Oncol. 2006, 25 (1-2): 173-188.
22. Ali SM, Olivo M: Bio-distribution and subcellular localization of Hypericin and its role in PDT induced apoptosis in cancer cells. Int J Oncol. 2002, 21 (3): 531-540.
23. Miccoli L, Oudard S, Sureau F, Poirson F, Dutrillaux B, Poupon MF: Intracellular pH governs the subcellular distribution of hexokinase in a glioma cell line. Biochem J. 1996, 313 (Pt 3): 957-962.
24. Miccoli L, Beurdeley-Thomas A, De Pinieux G, Sureau F, Oudard S, Dutrillaux B, Poupon MF: Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria. Cancer Res. 1998, 58 (24): 5777-5786.
25. Vantieghem A, Xu Y, Assefa Z, Piette J, Vandenheede JR, Merlevede W, De Witte PA, Agostinis P: Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. J Biol Chem. 2002, 277 (40): 37718-37731.
26. Assefa Z, Vantieghem A, Declercq W, Vandenabeele P, Vandenheede JR, Merlevede W, de Witte P, Agostinis P: The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin. J Biol Chem. 1999, 274 (13): 8788-8796.
27. Hendrickx N, Volanti C, Moens U, Seternes OM, de Witte P, Vandenheede JR, Piette J, Agostinis P: Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells. J Biol Chem. 2003, 278 (52): 52231-52239.
28. Hendrickx N, Dewaele M, Buytaert E, Marsboom G, Janssens S, Van Boven M, Vandenheede JR, de Witte P, Agostinis P: Targeted inhibition of p38alpha MAPK suppresses tumor-associated endothelial cell migration in response to hypericin-based photodynamic therapy. Biochem Biophys Res Commun. 2005, 337 (3): 928-935.
29. Wessels JT, Busse AC, Rave-Frank M, Zanker S, Hermann R, Grabbe E, Muller GA: Photosensitizing and radiosensitizing effects of hypericin on human renal carcinoma cells in vitro. Photochem Photobiol. 2008, 84 (1): 228-235.
30. Räz B, Iten M, Grether-Bühler Y, Kaminsky R, Brun R: The Alamar Blue® assay to determine drug sensitivity of African trypanosomes (< i>Tb rhodesienseandTb gambiense) in vitro. Acta Trop. 1997, 68 (2): 139-147.
31. Yuan Y-J, Ge Z-Q, Li J-C, Wu J-C, Hu Z-D: Differentiation of apoptotic and necrotic cells in suspension cultures of Taxus cuspidata by the combined use of fluorescent dying and histochemical staining methods. Biotechnol Lett. 2002, 24 (1): 71-76.
32. Shimizu S, Eguchi Y, Kamiike W, Itoh Y, Hasegawa J, Yamabe K, Otsuki Y, Matsuda H, Tsujimoto Y: Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res. 1996, 56 (9): 2161-2166.
33. Cossarizza A, Franceschi C, Monti D, Salvioli S, Bellesia E, Rivabene R, Biondo L, Rainaldi G, Tinari A, Malorni W: Protective effect of N-acetylcysteine in tumor necrosis factor-alpha-induced apoptosis in U937 cells: the role of mitochondria. Exp Cell Res. 1995, 220 (1): 232-240.
34. Garner DL, Thomas CA: Organelle-specific probe JC-1 identifies membrane potential differences in the mitochondrial function of bovine sperm. Mol Reprod Dev. 1999, 53 (2): 222-229.
35. Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F, Xu R: Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res. 2005, 65 (5): 1687-1692.
36. Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu R, Fan ST: FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis. 2004, 25 (12): 2397-2405.
37. Xu R, Harrison PM, Chen M, Li L, Tsui TY, Fung PC, Cheung PT, Wang G, Li H, Diao Y, Krissansen GW, Xu S, Farzaneh F: Cytoglobin overexpression protects against damage-induced fibrosis. Mol Ther. 2006, 13 (6): 1093-1100.
38. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014 [Epub ahead of print]
39. Agostinis P, Assefa Z, Vantieghem A, Vandenheede JR, Merlevede W, De Witte P: Apoptotic and anti-apoptotic signaling pathways induced by photodynamic therapy with hypericin. Adv Enzyme Regul. 2000, 40: 157-182.
40. Ali SM, Olivo M: Mechanisms of action of phenanthroperylenequinones in photodynamic therapy (review). Int J Oncol. 2003, 22 (6): 1181-1191.
41. Moor AC: Signaling pathways in cell death and survival after photodynamic therapy. J Photochem Photobiol B. 2000, 57 (1): 1-13.
42. Kiesslich T, Krammer B, Plaetzer K: Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. Curr Med Chem. 2006, 13 (18): 2189-2204.
43. Chao DT, Korsmeyer SJ: BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998, 16 (1): 395-419.
44. Kroemer G, Galluzzi L, Brenner C: Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007, 87 (1): 99-163.
45. Cheng C-Y, Su C-C: Tanshinone IIA may inhibit the growth of small cell lung cancer H146 cells by up-regulating the Bax/Bcl-2 ratio and decreasing mitochondrial membrane potential. Mol Med Reports. 2010, 3 (4): 645-650.
46. Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG, Huang DC, Cecconi F, Kuida K, Tomaselli KJ: Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature. 2002, 419 (6907): 634-637.
47. Pieper AA, Verma A, Zhang J, Snyder SH: Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci. 1999, 20 (4): 171-181.
48. Cregan SP, Dawson VL, Slack RS: Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene. 2004, 23 (16): 2785-2796.